Morgan Stanley Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $319
Benzinga Newsdesk 5 hours ago
Analyst RatingsNewsPrice Target
Morgan Stanley analyst Jeffrey Hung maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price target from $314 to $319.
Morgan Stanley analyst Jeffrey Hung maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price target from $314 to $319.